Insider Selling: Twist Bioscience (NASDAQ:TWST) Insider Sells $204,831.60 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) insider Dennis Cho sold 6,515 shares of the stock in a transaction dated Thursday, October 30th. The stock was sold at an average price of $31.44, for a total transaction of $204,831.60. Following the transaction, the insider directly owned 121,713 shares in the company, valued at $3,826,656.72. The trade was a 5.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Dennis Cho also recently made the following trade(s):

• On Monday, November 3rd, Dennis Cho sold 1,019 shares of Twist Bioscience stock. The shares were sold at an average price of $32.08, for a total value of $32,689.52.
• On Monday, October 6th, Dennis Cho sold 3,876 shares of Twist Bioscience stock. The stock was sold at an average price of $32.19, for a total value of $124,768.44.
• On Monday, September 22nd, Dennis Cho sold 233 shares of Twist Bioscience stock. The shares were sold at an average price of $27.56, for a total value of $6,421.48.
• On Monday, September 15th, Dennis Cho sold 94 shares of Twist Bioscience stock. The shares were sold at an average price of $25.33, for a total value of $2,381.02.
• On Monday, September 8th, Dennis Cho sold 269 shares of Twist Bioscience stock. The stock was sold at an average price of $25.76, for a total value of $6,929.44.

Twist Bioscience Stock Up 4.9%

TWST stock opened at $31.52 on Thursday. The firm has a market cap of $1.90 billion, a price-to-earnings ratio of -21.74 and a beta of 2.43. Twist Bioscience Corporation has a 1-year low of $24.07 and a 1-year high of $55.33. The firm has a fifty day moving average price of $29.18 and a two-hundred day moving average price of $31.74. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.90 and a quick ratio of 3.60.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, August 4th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.07. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. The business had revenue of $96.06 million during the quarter, compared to analyst estimates of $95.52 million. Research analysts predict that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on TWST shares. Evercore ISI decreased their target price on Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating for the company in a research note on Tuesday, October 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Wednesday, October 8th. Stephens initiated coverage on Twist Bioscience in a research note on Monday. They set an “overweight” rating and a $41.00 price objective for the company. Barclays cut their target price on Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating on the stock in a research note on Thursday, October 2nd. Finally, Cowen reissued a “buy” rating on shares of Twist Bioscience in a report on Monday, August 4th. Ten investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $47.80.

Institutional Trading of Twist Bioscience

Large investors have recently added to or reduced their stakes in the business. Smartleaf Asset Management LLC grew its stake in shares of Twist Bioscience by 70.6% in the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock worth $29,000 after purchasing an additional 442 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its stake in shares of Twist Bioscience by 90.4% during the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 265,851 shares of the company’s stock valued at $7,481,000 after purchasing an additional 126,260 shares in the last quarter. Envestnet Asset Management Inc. grew its position in Twist Bioscience by 19.8% in the 3rd quarter. Envestnet Asset Management Inc. now owns 49,840 shares of the company’s stock valued at $1,402,000 after buying an additional 8,246 shares in the last quarter. Thrivent Financial for Lutherans increased its stake in Twist Bioscience by 14.5% during the 3rd quarter. Thrivent Financial for Lutherans now owns 1,463,085 shares of the company’s stock valued at $41,171,000 after buying an additional 184,726 shares during the period. Finally, AlphaQuest LLC raised its position in shares of Twist Bioscience by 202.6% during the 3rd quarter. AlphaQuest LLC now owns 22,555 shares of the company’s stock worth $635,000 after buying an additional 15,101 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.